Skip to main content
. 2019 Aug 29;5(11):1556–1563. doi: 10.1001/jamaoncol.2019.2526

Figure 2. Kaplan-Meier Plot of Progression-Free Survival (PFS).

Figure 2.

A, Fulvestrant plus daily vistusertib vs fulvestrant (median PFS: fulvestrant plus daily vistusertib, 7.6 months; fulvestrant, 5.4 months; hazard ratio, 0.88 [95% CI, 0.63-1.24]; log-rank P = .46). B, Fulvestrant plus everolimus vs fulvestrant plus daily vistusertib (median PFS: fulvestrant plus everolimus, 12.3 months; fulvestrant plus daily vistusertib, 7.6 months; hazard ratio, 0.63 [95% CI, 0.45-0.90]; log-rank P = .01). C, Fulvestrant plus everolimus vs fulvestrant (median PFS: fulvestrant plus everolimus, 12.3 months; fulvestrant, 5.4 months; hazard ratio, 0.63 [95% CI, 0.42-0.92]; log-rank P = .01). D, Fulvestrant plus daily vistusertib vs fulvestrant plus intermittent vistusertib (median PFS: fulvestrant plus daily vistusertib, 7.6 months; fulvestrant plus intermittent vistusertib, 8.0 months; hazard ratio, 1.11 [95% CI, 0.81-1.52]; log-rank P = .52).